ALS Scandinavia
ALS Scandinavia is recorded as a service provider in 3 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 3 of 3 trials · Latest update first
(21196) A multicenter, prospective, open-label study to evaluate the pharmacokinetics and safety of gadoquatrane in pediatric participants (from birth to <18 years) undergoing contrast-enhanced magnetic resonance imaging (CE-MRI)
Sponsor Bayer AG
- Start (EU)
- Latest update
- Estimated end
(21197) A multicenter, randomized, prospective double-blind, cross over Phase 3 study to evaluate the efficacy and safety of 0.04 mmol Gd/kg body weight of gadoquatrane for MRI in adults with known or suspected pathology of any body region (except CNS), compared to 0.1 mmol Gd/kg approved macrocyclic gadolinium-based contrast agents (GBCAs)
Sponsor Bayer AG
- Start (EU)
- Latest update
- Estimated end
(21181) A multicenter, randomized, prospective double-blind, cross over Phase 3 study to evaluate the efficacy and safety of 0.04 mmol Gd/kg body weight of gadoquatrane for MRI in adults with known or suspected pathology of the central nervous system (CNS), compared to 0.1 mmol Gd/kg approved macrocyclic gadolinium-based contrast agents (GBCAs)
Sponsor Bayer AG
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for ALS Scandinavia?
The 2026-10-09 snapshot links ALS Scandinavia to 3 distinct CTIS trials. Recorded services include Laboratory services. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for ALS Scandinavia?
Therapeutic-area tags are not recorded in this snapshot. Study-phase tags are not recorded. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to ALS Scandinavia conducted?
The linked trials record locations in 8 countries, including Bulgaria, Czechia, Germany, Hungary, Italy. These are trial locations, not confirmed office locations or countries where ALS Scandinavia delivered services.
What can this page tell me about ALS Scandinavia's trial experience?
Browse 3 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under ALS Scandinavia. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- ALS Scandinavia AB